Souhaitez-vous accéder aux communiqués récents ?

ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- As generative AI reshapes the healthcare threat landscape, Pindrop today, announced its expansion into the healthcare industry, bringing AI-powered...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis...

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo®...

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated...

Entrada Therapeutics reports financial results for the fourth quarter and full year ended December 31, 2025, and highlights recent business updates.

AtaiBeckley today announced topline results from its Phase 2a study evaluating EMP‑01 (oral R‑MDMA) in adults with Social Anxiety Disorder.

Ottawa, Feb. 26, 2026 (GLOBE NEWSWIRE) -- According to Precedence Research, the global large language model market size will grow from USD 10.57 billion in 2026 to nearly USD 149.89 billion by 2035,...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "Personalized Medicine Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ...